Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

The companion product – Susvimo – is an implantable treatment based on ranibizumab that can extend the time between treatments to six months or more and was approved by the FDA last October.

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of June 2025. The chart below provides highlights of key monograph updates ...

Global News Select May 23, 2025, 2:23:00 PM Roche's Susvimo Gets FDA Green Light for Treatment of Diabetic Retinopathy Global News Select May 22, 2025, 9:20:00 AM ...

FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma SOUTH SAN FRANCISCO, Calif ...